At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Pemetrexeddrug
Likely dose
Pemetrexed 900 mg/m² IV over 10 minutes every 21 days (700 mg/m² for patients with prior radiotherapy)AI-extracted
Key inclusion· 4
- ✓Recurrent squamous or non-squamous cell carcinoma of the cervix with documented disease progression
- ✓Measurable disease present
- ✓One prior systemic chemotherapy for persistent or recurrent disease required
- ✓GOG performance status 0-2
Key exclusion· 3
- ✕Prior pemetrexed treatment
- ✕Radiation to more than 25% of bone marrow-bearing areas
- ✕Other malignancy within last 5 years (except non-melanoma skin cancer)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix
In Brief
A Phase 2 clinical trial evaluating Pemetrexed for Cervical Intraepithelial Neoplasia and 2 related conditions. Completed, enrolled 29 participants across 1 site.
Detailed Summary
This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsGynecologic Oncology Group
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2005
First PostedSep 2005
Primary CompletionOct 2007
TodayJul 2026
First PostedSep 19, 2005
Enrollment StartFeb 1, 2005
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 20.8 years ago
Interventions
Pemetrexeddrug
Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.